Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: A population-based cohort study

Pain

Volumn 157, Issue 9, 2016, Pages 1954-1959

  Hou, Wen Hsuan ^a,b   Chang, Kai Cheng ^c   Li, Chung Yi ^c,d   Ou, Huang Tz ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cohort; Dipeptidyl peptidase 4 inhibitor; Severe joint pain; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; ANTIDIABETIC AGENT;

ADULT; ARTHRALGIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; SEVERE JOINT PAIN; AGED; DIABETES MELLITUS, TYPE 2; HEALTH CARE PLANNING; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; TAIWAN;

ADULT; AGED; ARTHRALGIA; COHORT STUDIES; COMMUNITY HEALTH PLANNING; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; TAIWAN;

EID: 84984636483     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000596     Document Type: Article

References (37)

1. Adamson J, Ebrahim S, Dieppe P, Hunt K. Prevalence and risk factors for joint pain among men and women in the West of Scotland Twenty-07 study. Ann Rheum Dis 2006;65:520-4
2. Administration USFaD. FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain, 2015. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm. Accessed 16 January, 2016
3. Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B,O'Shea D. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Dermatol Venereol 2013;27:1440-3
4. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80
5. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298: 194-206
6. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study G. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
7. Chang CH, Shau WY, Jiang YD, Li HY, Chang TJ, Sheu WH, Kwok CF, Ho LT, Chuang LM. Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999-2004: a national health insurance data set study. Diabet Med 2010;27:636-43
8. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted diabetes Complications severity index in claims data. Am J Manag Care 2012;18:721-6
9. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51
10. Chen HF, Ho CA, Li CY. Age and sex may significantly interact with diabetes on the risks of lower-extremity amputation and peripheral revascularization procedures: evidence from a cohort of a half-million diabetic patients. Diabetes Care 2006;29:2409-14
11. Chen HL, Hsiao FY. Risk of hospitalization and healthcare cost associated with diabetes Complication severity index in Taiwan's national health insurance research Database. J Diabetes Complications 2014;28:612-16
12. Crickx E, Marroun I, Veyrie C, Le Beller C, Schoindre Y, Bouilloud F, Bletry O, Kahn JE. DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatol Int 2014;34:291-2
13. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, doubleblind, placebo-controlled study. Diabetes Care 2008;31:2315-17
14. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
15. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-83
16. Gay A, Culliford D, Leyland K, Arden NK, Bowen CJ. Associations between body mass index and foot joint pain in middle-aged and older women: a longitudinal population-based cohort study. Arthritis Care Res 2014;66:1873-9
17. Gerli R, Muscat C, Bertotto A, Bistoni O, Agea E, Tognellini R, Fiorucci G, Cesarotti M, Bombardieri S. CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin Immunol Immunopathol 1996;80:31-7
18. Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, Weiner HL. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 2000;57:1183-9
19. Kidwai SS, Wahid L, Siddiqi SA, Khan RM, Ghauri I, Sheikh I. Upper limb musculoskeletal abnormalities in type 2 diabetic patients in low socioeconomic strata in Pakistan. BMC Res Notes 2013;6:16
20. Muscat C, Bertotto A, Agea E, Bistoni O, Ercolani R, Tognellini R, Spinozzi F, Cesarotti M, Gerli R. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994;98:252-6
21. Ohnuma K, Hosono O, Dang NH, Morimoto C. Dipeptidyl peptidase in autoimmune pathophysiology. Adv Clin Chem 2011;53:51-84
22. Ospelt C, Mertens JC, Jungel A, Brentano F, Maciejewska-Rodriguez H, Huber LC, Hemmatazad H, Wuest T, Knuth A, Gay RE, Michel BA, Gay S, Renner C, Bauer S. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010;62:1224-35
23. Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC, Li SY, Chen YT. Effects on clinical outcomes of adding dipeptidyl Peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 2015;163:663-72
24. Parsons LS, editor. "Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques". Proceedings of the Twenty-Sixth Annual SASâUsers Group International Conference, Cary, NC: SAS Institute Inc., 2001; http://www2.sas.com/proceedings/ sugi26/p214-26.pdf
25. Ramchurn N, Mashamba C, Leitch E, Arutchelvam V, Narayanan K, Weaver J, Hamilton J, Heycock C, Saravanan V, Kelly C. Upper limb musculoskeletal abnormalities and poor metabolic control in diabetes. Eur J Intern Med 2009;20:718-21
26. Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. CMAJ 2002;167:1253-60
27. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63
28. Saito T, Ohnuma K, Suzuki H, Dang NH, Hatano R, Ninomiya H, Morimoto C. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. Diabetes Res Clin Pract 2013;102:e8-e12
29. Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 2005;7:253-69
30. Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010;88:125-31
31. Sulsky SI, Carlton L, Bochmann F, Ellegast R, Glitsch U, Hartmann B, Pallapies D, Seidel D, Sun Y. Epidemiological evidence for work load as a risk factor for osteoarthritis of the hip: a systematic review. PloS One 2012;7:e31521
32. Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol 1997;19:15-24
33. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1-248
34. Williams YN, Baba H, Hayashi S, Ikai H, Sugita T, Tanaka S, Miyasaka N, Kubota T. Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin Exp Immunol 2003;131:68-74
35. Wong PT, Wong CK, Tam LS, Li EK, Chen DP, Lam CW. Decreased expression of T lymphocyte co-stimulatory molecule CD26 on invariant natural killer T cells in systemic lupus erythematosus. Immunol Invest 2009;38:350-64
36. Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003;33:1519-27
37. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7